Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size

Abstract

The aim of this study was to determine, in an animal model, the effects of tadalafil on myocardial infarct size (IS), hemodynamics and regional myocardial blood flow after myocardial ischemia and reperfusion. Patients with erectile dysfunction (ED) often have risk factors for coronary artery disease. Tadalafil, a long-acting inhibitor of the enzyme phosphodiesterase-5 (PDE5), is used for the treatment of ED; there are no previous data regarding tadalafil in the setting of coronary artery occlusion (CAO). Sprague–Dawley male rats were treated with tadalafil or vehicle (10 mg/kg, by gastric gavage), 2 h before a 30 min CAO. Heart rate was comparable between tadalafil and control groups. Tadalafil reduced mean arterial pressure (P=0.009), systolic (P=0.035) and diastolic (P=0.009) blood pressures during ischemia/reperfusion. Tadalafil significantly reduced IS (42±2%) versus controls (54±3%) (P=0.006). For the first time, we showed that the PDE5 inhibitor, tadalafil, was well tolerated and cardioprotective in the setting of an experimental myocardial infarction, by substantially reducing ischemic cell death.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5

Similar content being viewed by others

References

  1. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB . Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

  2. Laumann EO, Paik A, Rosen RC . Sexual dysfunction in United States: prevalence and predictors. JAMA 1999; 281: 537–544.

    Article  CAS  Google Scholar 

  3. Blumentals WA, Gomez-Caminero A, Joo S, Vannappaggari V . Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res 2004; 16: 350–353.

    Article  CAS  Google Scholar 

  4. Kaiser DR, Billups K, Mason C, Wetterling R, Lundberg JL, Bank AJ . Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol 2004; 43: 179–184.

    Article  Google Scholar 

  5. Kloner RA, Jarow JP . Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol 1999; 83: 576–582.

    Article  CAS  Google Scholar 

  6. Aversa A, Pili M, Fabbri A, Spera E, Spera G . Erectile dysfunction: expectations beyond phosphodiesterase type-5 inhibition. J Endocrinol Invest 2004; 27: 192–206.

    Article  CAS  Google Scholar 

  7. Kloner RA . Cardiovascular effects of the 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation 2004; 110: 3149–3155.

    Article  Google Scholar 

  8. Jackson G, Kloner RA, Costigan TM, Warner MR, Emmick JT . Update on clinical trials of tadalafil demonstrates no increased risk of cardiovascular adverse effects. J Sex Med 2004; 1: 161–167.

    Article  CAS  Google Scholar 

  9. Kloner RA, Padma-Nathan H . Erectile dysfunction in patients with coronary artery disease. Int J Impot Res 2005; 17: 209–215.

    Article  CAS  Google Scholar 

  10. Kukrejia RC, Ockaili R, Salloum F, Yin C, Hawkins J, Das A et al. Cardioprotection with phosphodiesterase-5 inhibition – a novel preconditioning strategy. J Mol Cell Cardiol 2003; 36: 165–173.

    Article  Google Scholar 

  11. Rosano GMC, Aversa A, Vitale C, Fabbri A, Fini M, Spera G . Chronic treatment with tadalafil improves endothelial function in men with increased cardiovascular risk. Eur Urol 2005; 47: 214–222.

    Article  CAS  Google Scholar 

  12. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214–222.

    Article  CAS  Google Scholar 

  13. Ockaili R, Salloum F, Hawkins J, Kukreja RC . Sildenafil (Viagra) induces powerful cardioprotective effect via opening of mitochondrial KATP channels in rabbits. Am J Physiol Heart Circ Physiol 2002; 283: H1263–H1269.

    Article  CAS  Google Scholar 

  14. Rosen RC, Kostis JB . Overview of phosphodiesterase 5 inhibition in erectile dysfunction. Am J Cardiol 2003; 92 (Suppl): 9M–18M.

    Article  CAS  Google Scholar 

  15. Kloner RA, Mitchell M, Emmick JT . Cardiovascular effects of tadalafil. Am J Cardiol 2003; 92 (Suppl): 37M–46M.

    Article  CAS  Google Scholar 

  16. Kloner RA, Mitchell M, Emmick JT . Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol 2003; 92 (Suppl): 47M–57M.

    Article  CAS  Google Scholar 

  17. American Heart Association. Position of the American Heart Association on research animal use. Circulation 1985; 71: 849A–850A.

  18. Heymann MA, Payne BD, Hoffman JE, Rudolph AM . Blood flow measurement with radionuclide-labeled particles. Prog Cardiovasc Dis 1977; 20: 55–79.

    Article  CAS  Google Scholar 

  19. Bischoff E . Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 2004; 16 (Supp 1): S11–S14.

    Article  CAS  Google Scholar 

  20. Carson CC, Rajfer J, Eardley I, Carrier S, Dennes JS, Walker DJ et al. The efficacy and safety of tadalafil: an update. BJU Int 2004; 39: 1276–1281.

    Article  Google Scholar 

  21. Montorsi F, Padma Nathan H, McCullough A, Brock GB, Broderick G, Ahuja S et al. Tadalafil in the treatment of erectile dysfunction following bilateral nerve-sparing radical retropubic prostatectomy: a randomized, double-blind, placebo-controlled trial. J Urol 2004; 172: 1036–1041.

    Article  CAS  Google Scholar 

  22. Sastry BK, Narasimhan C, Reddy NK, Raju BS . Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 2004; 43: 1149–1153.

    Article  CAS  Google Scholar 

  23. Tantini B, Manes A, Fiumana E, Pignatti C, Guarnieri C, Zannoli R et al. Antiproliferative effect of sildenafil on human pulmonary artery smooth muscle cells. Basic Res Cardiol 2005; 100: 131–138.

    Article  CAS  Google Scholar 

  24. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S . Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 2000; 36: 845–851.

    Article  CAS  Google Scholar 

  25. Desouza C, Parulkar A, Lumpkin D, Akers D, Fonseca VA . Acute and prolonged effects of sildenafil on brachial artery flow-mediated dilatation in type-2 diabetes. Diabetes Care 2002; 25: 1336–1339.

    Article  CAS  Google Scholar 

  26. Kimura M, Higashi Y, Hara K, Noma K, Sasaki S, Nakagawa K et al. PDE5 inhibitor sildenafil citrate augments endothelium-dependent vasodilation in smokers. Hypertension 2003; 41: 1106–1110.

    Article  CAS  Google Scholar 

  27. Reffelmann T, Kloner RA . Effects of sildenafil on myocardial infarct size, microvascular function, and acute ischemic left ventricular dilation. Cardiovasc Res 2003; 59: 441–449.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to R A Kloner.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sesti, C., Florio, V., Johnson, E. et al. The phosphodiesterase-5 inhibitor tadalafil reduces myocardial infarct size. Int J Impot Res 19, 55–61 (2007). https://doi.org/10.1038/sj.ijir.3901497

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901497

Keywords

This article is cited by

Search

Quick links